Komori
Business partnership4534Mochida Pharmaceutical Co.,Ltd.Pharmaceuticals

Notice of the Execution of a Comprehensive Partnership Agreement Concerning Biosimilars

Mochida Pharmaceutical Co., Ltd. has entered into a comprehensive collaboration agreement with Qilu Pharmaceutical Co., Ltd. to jointly develop and commercialize multiple Qilu biosimilars in Japan. The collaboration will expand from cooperation on individual products to medium- to long-term cooperation covering multiple products.

Worth reading
35Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Agreements reached under this partnership

Business partnership
4534Mochida Pharmaceutical Co.,Ltd.
Alliance partnerQilu Pharmaceutical Co., Ltd.
Details of the alliance
  1. 1

    Collaboration by Mochida Pharmaceutical Co., Ltd. on development and commercialization in Japan

These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.

About the partner
Business DescriptionOne of China's leading pharmaceutical companies, with an integrated presence across research and development, manufacturing and sales.
LocationJinan, Shandong Province, China
Net Sales2025: Approximately US$6 billion
Agreements reached under this partnership
ItemDetails
Name of alliance partnerQilu Pharmaceutical Co., Ltd.
Alliance partner's business activitiesOne of China's leading pharmaceutical companies, with an integrated presence across research and development, manufacturing and sales.
Alliance partner's locationJinan, Shandong Province, China
Alliance partner's net sales2025: Approximately US$6 billion
Type of allianceBusiness partnership
Details of the allianceCollaboration by Mochida Pharmaceutical Co., Ltd. on development and commercialization in Japan
Items this document does not state (17)
Alliance partner's capitalAlliance partner's operating incomeNumber of shares acquiredAcquisition priceShareholding ratioOverview of the joint ventureOwnership ratioDispatch of directors and officersContract PeriodNumerical targets under the allianceShareholding PolicyDate of board resolutionContract DateAlliance start dateShare Acquisition Date and Payment DateImpact on Business PerformanceChange in major shareholders

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

As a result of considering the potential for further collaboration in the biosimilars field through the collaboration on the follitropin alfa biosimilar that has been under way since March 2026, the parties agreed to promote collaboration on multiple biosimilars from a medium- to long-term perspective, rather than limiting the collaboration to individual products.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of the Execution of a Comprehensive Partnership Agreement Concerning Biosimilars | Mochida Pharmaceutical Co.,Ltd. (4534) timely disclosure | Komori